Physician profile
Ravi Mishra
NPI 1093058018
$4,620.61
in general payments reported to CMS, 2019-2025
24 companies · $196 in 2025
The $196 reported for 2025 was more than what 76% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $994 · 2020: $580 · 2021: $710 · 2022: $868 · 2023: $817 · 2024: $455 · 2025: $196.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,468.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,139.76 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $568.70 | 2019-2023 | |
| Inari Medical, INC. | $444.15 | 2021-2023 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $273.74 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $273.08 | 2019-2023 | Camzyos |
| Gilead Sciences, INC. | $253.45 | 2022-2024 | Veklury |
| Allergan, INC. | $217.30 | 2019-2020 | |
| Boston Scientific Corporation | $188.19 | 2020-2025 | Farapulse |
| Pfizer INC. | $183.91 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $164.92 | 2019-2025 | Jardiance |
| Abbvie INC. | $143.74 | 2021-2024 | |
| Portola Pharmaceuticals, LLC | $136.54 | 2019-2020 | |
| Mylan Specialty L.P. | $133.94 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $128.31 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $73.75 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $61.14 | 2021-2022 | |
| Angiodynamics, INC. | $46.61 | 2024-2025 | Angiovac |
| Abbott Laboratories | $38.74 | 2019 | |
| Biomerieux INC | $35.45 | 2019 | |
| Csl Behring | $29.36 | 2019 | |
| Alexion Pharmaceuticals, INC. | $24.35 | 2022 | |
| Novo Nordisk INC | $23.81 | 2021 | |
| Janssen Biotech, INC. | $20.32 | 2024 | Rybrevant |
| Otsuka America Pharmaceutical, INC. | $17.35 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ravi Mishra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.